en · de · es · fr · pt
dihexa-notes.peptides1126.com › Info › Overview And Research Status — Reference Sheet

Overview And Research Status — Reference Sheet

By Editorial Desk · published 2026-06-11 · last reviewed 2026-07-01 · Info

peptide analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-07-01 and is reviewed periodically as new material appears.

Overview and Research Status

Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.

Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.

Handling, Analysis, and Regulatory Status

Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.

Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.

Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.

Dihexa at a glance

PropertyValueNotes
CAS Registry Number1401708-83-5Identifier used in chemical databases.
Common synonymsP21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide)Names vary by supplier and publication.
Physical formWhite to off-white powderLyophilized solid typical of peptides.
SolubilitySoluble in DMSO; limited in waterAqueous preparation may need a co-solvent.
Storage-20 °C, desiccated, protected from lightReduce freeze-thaw cycles to maintain stability.

Proposed Mechanism and Laboratory Handling

Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.

Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.

The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.

Related pages on this site

Dihexa Chemical Identity and Origin

Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.

The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.

Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.

Further detail

=== Human serum prolidase === Two 493 amino acid chains construct serum prolidase, held together with C2 symmetry. This C2 symmetry refers to the molecule's two-fold rotational symmetry without mirror symmetry. Simply put, if serum prolidase were to be rotated at a 180º angle, it would look the same, however, it does not look the same in a mirror image. Furthermore, this structure has two domains: the N-terminal domain and the C-terminal domain, the latter of which carries the active site in the amino acid residues 185-493. The active site is the area on the enzyme to which the substrate binds and catalysis occurs. This C-terminal domain has the ability to covalently bond to other prolidase enzymes to create a tetramer through disulfide bonds. This domain performs a "pita-bread" fold, consisting of a bimetallic active center held together by two ɑ-helices and one antiparallel β-sheet. Prolidase enzyme is considered homodimeric, meaning it is formed by two identical polypeptide chains. There are both hydrophilic and hydrophobic residues in this enzyme, distributed evenly throughout. Manganese ions (Mn2+) are utilized by serum prolidase as co-factors. Research into the crystal structure has found that two Mn2+ ions are required for the catalytic activity of this enzyme. This requirement leads to prolidase being deemed a metal-activated peptidase, a term used to describe enzymes that catalyze the hydrolysis reaction changing peptides into amino acids having increased ability through the existence of metal ions.

A total of 18 different kavalactones (or kavapyrones) have been identified to date, at least 15 of which are active. However, six of them, including kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin, have been determined to be responsible for about 96% of the plant's pharmacological activity. Some minor constituents, including three chalcones—flavokavain A, flavokavain B, and flavokavain C—have also been identified, as well as a toxic alkaloid (not present in the consumable parts of the plant), pipermethystine. Alkaloids are present in the roots and leaves.

== Medical uses == Datopotamab deruxtecan is indicated for the treatment of adults with unresectable or metastatic, hormone receptor positive, human epidermal growth factor receptor 2-negative (IHC 0, IHC1+ or IHC2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. In June 2025, the US Food and Drug Administration (FDA) expanded the indication to include the treatment of adults with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer who have received prior epidermal growth factor receptor-directed therapy and platinum-based chemotherapy. In May 2026, the FDA expanded the indication to include the treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.

Sources: en.wikipedia.org

Supporting material

==== Harry Potter partnership ==== In August 2026, Tim Horton announced that it would be releasing a series of themed menu items to mark the 25th anniversary of the release of the first film of the Harry Potter movie franchise as part of its “Back to Hogwarts with Harry Potter” campaign. Menu items included themed donuts and drinks. Harry Potter-themed "quiz nights" were also held at selected stores across Canada.

Other methods of preservation include the storage of specimens in spirit. Such wet specimens have special value in physiological and anatomical study, apart from providing better quality of DNA for molecular studies. Freeze drying of specimens is another technique that has the advantage of preserving stomach contents and anatomy, although it tends to shrink, making it less reliable for morphometrics.

=== Surgery === Weight loss surgery in those with obesity and type 2 diabetes is often an effective measure. Many are able to maintain normal blood sugar levels with little or no medications following surgery and long-term mortality is decreased. There is, however, a short-term mortality risk of less than 1% from the surgery. The body mass index cutoffs for when surgery is appropriate are not yet clear. It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control. A pancreas transplant is occasionally considered for people with type 1 diabetes who have severe complications of their disease, including end stage kidney disease requiring kidney transplantation. Diabetic peripheral neuropathy (DPN) affects 30% of all diabetes patients. When DPN is superimposed with nerve compression, DPN may be treatable with multiple nerve decompressions. The theory is that DPN predisposes peripheral nerves to compression at anatomical sites of narrowing, and that the majority of DPN symptoms are actually attributable to nerve compression, a treatable condition, rather than DPN itself. The surgery is associated with lower pain scores, higher two-point discrimination (a measure of sensory improvement), lower rate of ulcerations, fewer falls (in the case of lower extremity decompression), and fewer amputations.

Connolly, who was still at the club in 2013 but serving in a role outside the football department, was suspended outright from serving in any position at any club until 1 February 2014. Connolly was sacked by Melbourne in October 2013. Bailey, serving in 2013 as an assistant coach at the Adelaide Crows, was suspended from his position for the first sixteen weeks of the 2013 season, preventing him from having any contact with the Crows' playing group during that time. The Melbourne Football Club, which was complicit to the infraction in its capacity as Connolly's and Bailey's employer, was fined $500,000. None of Melbourne, Connolly or Bailey contested these penalties.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.

Is dihexa approved for human use?

No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.

What is dihexa studied for?

Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.

How should dihexa be stored?

The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.

Network